MedPath

Biomarkers in Chronic Arthritis

Completed
Conditions
Chronic Arthritis
Registration Number
NCT02909998
Lead Sponsor
University Hospital, Montpellier
Brief Summary

Use of genotyping for the optimization of treatment with biologics in chronic arthritis by looking for an association between certain alleles and response to treatment.

Detailed Description

Chronic arthritis in children and in adults represent a public health problem in number and difficulty of treatment. 30% of patients are non-responders and / or relapse upon discontinuation of treatment. Some of these treatments are not always well tolerated, sometimes with infectious complications including tuberculosis limiting the use of biological therapies. This study will validate a battery of genetic markers to predict responders biotherapy, determine the prognosis of patients, these treatments are reserved for the most severe forms, and thus improve the care of patients.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
379
Inclusion Criteria
  • All patients treated with biotherapy may be included in this study with all information necessary for regular medical consultations (filling specific monitoring by GPs questionnaires), physical therapists visits, occupational therapists, psychologists.. etc
Exclusion Criteria
  • Patients treated with biological therapy for non rheumatic disease
  • Other inflammatory diseases such as Crohn's disease
  • Refusal to participate in the collection

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Proportion of responsive patients with a given polymorphism (%)At the inclusion
Secondary Outcome Measures
NameTimeMethod
Distribution of patients with a given biotherapy (%)At the inclusion
Distribution of patients presenting a given polymorphism (%)At the inclusion
© Copyright 2025. All Rights Reserved by MedPath